Discovery of orally bioavailable ALK PROTACs based Ceritinib against ALK positive cancers-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Discovery of orally bioavailable ALK PROTACs based Ceritinib against ALK positive cancers

Published:2024-09 Issue: Volume: Page:116827
ISSN:0223-5234
Container-title:European Journal of Medicinal Chemistry
language:en
Short-container-title:European Journal of Medicinal Chemistry

Author:

Zhou Haoxuan,Hu Mingxing,Jie Hui,Li Yujue,Tang Kexin,Pan LiLi,Liu Chengyali,liu scheZi,Chen Wei,Chen Yuanwei,Luo Yi,Gong Youling,Xie Yongmei^ORCID

Funder

National Natural Science Foundation of China

Sichuan University

West China Hospital, Sichuan University

National Natural Science Foundation of China-Guangdong Joint Fund

Science and Technology Department of Sichuan Province

Publisher

Elsevier BV

Reference35 articles.

1. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-hodgkin's lymphoma;Morris;Science,1994

2. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007

3. Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor;Debelenko;Lab Invest,2003

4. ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma;De Paepe;Blood,2003

5. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine;Katayama;Clin Cancer Res,2015

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP